Search Results | Blood | American Society of Hematology

1-20 of 52

2 3

Sort by

Sort Order Select

Journal Articles

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Murielle Roussel, Valérie Lauwers-Cances, Margaret Macro, Xavier Leleu, Bruno Royer, Cyrille Hulin, Lionel Karlin, Aurore Perrot, Cyrille Touzeau, Marie-Lorraine Chrétien, Sophie Rigaudeau, Mamoun Dib, Emmanuelle Nicolas-Virelizier, Martine Escoffre-Barbe, Karim Belhadj, Clara Mariette, Anne-Marie Stoppa, Carla Araujo, Chantal Doyen, Jean Fontan, Brigitte Kolb, Laurent Garderet, Sabine Brechignac, Jean-Valère Malfuson, Arnaud Jaccard, Pascal Lenain, Cécile Borel, Benjamin Hebraud, Omar Benbrahim, Véronique Dorvaux, Salomon Manier, Karine Augeul-Meunier, Marie-Christiane Vekemans, Edouard Randriamalala, Driss Chaoui, Jo Caers, Carine Chaleteix, Lofti Benboubker, Laure Vincent, Sylvie Glaisner, Patricia Zunic, Borhane Slama, Jean-Richard Eveillard, Catherine Humbrecht-Kraut, Véronique Morel, Philippe Mineur, Jean-Claude Eisenmann, Hélène Demarquette, Valentine Richez, Marguerite Vignon, Denis Caillot, Thierry Facon, Philippe Moreau, Anne-Laurène Colin, Pascale Olivier, Soraya Wuilleme, Hervé Avet-Loiseau, Jill Corre, Michel Attal

Blood (2022) 139 (18): 2747–2757.

DOI: https://doi.org/10.1182/blood.2021014635

Published: 2022

Includes: Supplemental data

Journal Articles

Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features

Blood (2022) 139 (17): 2666–2672.

DOI: https://doi.org/10.1182/blood.2021014968

Published: 2022

Includes: Supplemental data

Journal Articles

SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma

Sahar Kassem, Béré K. Diallo, Nizar El-Murr, Nadège Carrié, Alexandre Tang, Alain Fournier, Hélène Bonnevaux, Céline Nicolazzi, Marine Cuisinier, Isabelle Arnould, Sukhvinder S. Sidhu, Jill Corre, Hervé Avet-Loiseau, Jean-Luc Teillaud, Helgi van de Velde, Dmitri Wiederschain, Marielle Chiron, Ludovic Martinet, Angela Virone-Oddos

Blood (2022) 139 (8): 1160–1176.

DOI: https://doi.org/10.1182/blood.2021012448

Published: 2022

Includes: Supplemental data

Journal Articles

IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM

Abdul Hamid Bazarbachi, Hervé Avet-Loiseau, Raphael Szalat, Anil Aktas Samur, Zachary Hunter, Masood Shammas, Jill Corre, Mariateresa Fulciniti, Kenneth C. Anderson, Giovanni Parmigiani, Steven P. Treon, Mohamad Mohty, Nikhil C. Munshi, Mehmet Kemal Samur

Blood (2021) 138 (20): 1980–1985.

DOI: https://doi.org/10.1182/blood.2021011452

Published: 2021

Includes: Supplemental data

Journal Articles

16p Deletion Involving BCMA Locus Is Frequent and Predominantly Observed with del17p

Mehmet K. Samur, Anil Aktas-Samur, Romain Lannes, Jill Corre, Anjan Thakurta, Kenneth C. Anderson, Herve Avet-Loiseau, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 1590.

DOI: https://doi.org/10.1182/blood-2021-152286

Published: 2021

Journal Articles

Multiomic Mapping of Copy Number and Structural Variation on Chromosome 1 (Chr1) Highlights Multiple Recurrent Disease Drivers

Blood (2021) 138 (Supplement 1): 721.

DOI: https://doi.org/10.1182/blood-2021-148439

Published: 2021

Journal Articles

Defining Genomic Probability of Progression to Identify Low-Risk Smoldering Multiple Myeloma

Anil Aktas-Samur, Mariateresa Fulciniti, Sanika Derebail, Raphael Szalat, Giovanni Parmigiani, Jill Corre, Herve Avet-Loiseau, Mehmet K. Samur, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 545.

DOI: https://doi.org/10.1182/blood-2021-152317

Published: 2021

Journal Articles

Presence of Extrachromosomal DNA (ecDNA) Impacts Both Progression Free and Overall Survival and Is an Independent Poor Prognostic Marker in Multiple Myeloma

Parth Shah, Anil Aktas-Samur, Mariateresa Fulciniti, Raphael Szalat, Masood A. Shammas, Paul G. Richardson, Florence Magrangeas, Stephane Minvielle, Aurore Perrot, Jill Corre, Philippe Moreau, Anjan Thakurta, Kenneth C. Anderson, Herve Avet-Loiseau, Nikhil C. Munshi, Mehmet K. Samur

Blood (2021) 138 (Supplement 1): 461.

DOI: https://doi.org/10.1182/blood-2021-151647

Published: 2021

Journal Articles

Clonal Hematopoiesis Is Frequent and Associated with Inferior Survival Irrespective of Transplantation Strategy in Patients with Newly Diagnosed Multiple Myeloma

Adam S. Sperling, Robert Redd, Christopher J. Gibson, Peter G. Miller, Jill Corre, Philippe Moreau, Donna S. Neuberg, Mehmet K. Samur, Benjamin L. Ebert, Herve Avet-Loiseau, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 1127.

DOI: https://doi.org/10.1182/blood-2021-148050

Published: 2021

Journal Articles

In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present from the Diagnosis in Tiny Undetectable Subclones

Blood (2021) 138 (Supplement 1): 77.

DOI: https://doi.org/10.1182/blood-2021-146869

Published: 2021

Journal Articles

Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2

Blood (2021) 138 (Supplement 1): 82.

DOI: https://doi.org/10.1182/blood-2021-147897

Published: 2021

Journal Articles

Why is amyloidosis not multiple myeloma?

Jill Corre

Blood (2021) 138 (17): 1514–1515.

DOI: https://doi.org/10.1182/blood.2021012973

Published: 2021

Journal Articles

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Murielle Roussel, Valerie Lauwers-Cances, Soraya Wuilleme, Karim Belhadj, Salomon Manier, Laurent Garderet, Martine Escoffre-Barbe, Clara Mariette, Lotfi Benboubker, Denis Caillot, Cécile Sonntag, Cyrille Touzeau, Jehan Dupuis, Philippe Moreau, Xavier Leleu, Thierry Facon, Benjamin Hébraud, Jill Corre, Michel Attal

Blood (2021) 138 (2): 113–121.

DOI: https://doi.org/10.1182/blood.2021010744

Published: 2021

Journal Articles

del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma

Blood (2021) 137 (9): 1192–1195.

DOI: https://doi.org/10.1182/blood.2020008346

Published: 2021

Includes: Supplemental data

Journal Articles

Risk factors in multiple myeloma: is it time for a revision?

Jill Corre, Nikhil C. Munshi, Hervé Avet-Loiseau

Blood (2021) 137 (1): 16–19.

DOI: https://doi.org/10.1182/blood.2019004309

Published: 2021

Journal Articles

Undetectable MRD can change the deal

Jill Corre

Blood (2021) 137 (1): 5–6.

DOI: https://doi.org/10.1182/blood.2020008090

Published: 2021

Journal Articles

The Discriminatory Ability of the R-ISS Is Equivalent to the ISS in a Large Cohort of Newly Diagnosed Multiple Myeloma (NDMM) Patients

Anaïs Schavgoulidze, Valerie Lauwers-Cances, Aurore Perrot, Herve Avet-Loiseau, Jill Corre, PharmD, PhD

Blood (2020) 136 (Supplement 1): 46–47.

DOI: https://doi.org/10.1182/blood-2020-136996

Published: 2020

Journal Articles

Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study

Rosalinda Termini, Evangelos Terpos, MDPhD, Albert Pérez, MD, Tomas Jelinek, Nikoletta-Aikaterini Kokkali, Joan Bargay, MD, Fernando Solano Ramos, MD PhD, Sara Rodríguez, PhD, Cristina Pérez Ruiz, Catarina Maia, Antonio Sacco, RN, Marco Chiarini, MSc, Viviana Giustini, MSc, Jill Corre, PharmD, PhD, Francois Vergez, DVM, PhD, Marc S. Raab, MD, Niels Weinhold, PhD, Aitziber Lopez Lopez, Sonia Garate, Diego Alignani, PhD, Sarvide Sarai, Remco Loos, Antoni Garcia-Guiñon, MD, Maialen Sirvent, José Enrique de la Puerta, Rebeca Iglesias, Maria Casanova, MD, Maria Elena Cabezudo, Valentin Cabañas, MD, Enrique M. Ocio, MDPhD, Joaquin Martinez-Lopez, MD, Javier de la Rubia, Artur Paiva, Helena Vitoria, Catarina Geraldes, MD PhD, Roman Hajek, MD, Heinz Ludwig, MD, Hartmut Goldschmidt, MD, Herve Avet-Loiseau, Aldo M. Roccaro, MDPhD, Jesús F. San-Miguel, Bruno Paiva, PhD

Blood (2020) 136 (Supplement 1): 1–2.

DOI: https://doi.org/10.1182/blood-2020-136251

Published: 2020

Journal Articles

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

Mehmet K. Samur, PhD, Marco Roncador, MD MSc, Anil Aktas-Samur, PhD, Mariateresa Fulciniti, PhD, Abdul Hamid Bazarbachi, MD, Raphael Szalat, Masood A. Shammas, PhD, Adam S Sperling, MD PhD, Paul G. Richardson, MD, Florence Magrangeas, Stephane Minvielle, PhD, Anjan Thakurta, Aurore Perrot, Jill Corre, PharmD, PhD, Philippe Moreau, MD, Kenneth Anderson, MD, Giovanni Parmigiani, PhD, Herve Avet-Loiseau, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 4–5.

DOI: https://doi.org/10.1182/blood-2020-139014

Published: 2020

Journal Articles

High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma

Anil Aktas-Samur, PhD, Mariateresa Fulciniti, PhD, Sanika Derebail, MS, Raphael Szalat, Giovanni Parmigiani, PhD, Jill Corre, PharmD, PhD, Herve Avet-Loiseau, Mehmet K. Samur, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 2.

DOI: https://doi.org/10.1182/blood-2020-139066

Published: 2020

2 3

NARROW

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features

SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma

IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM

16p Deletion Involving BCMA Locus Is Frequent and Predominantly Observed with del17p

Multiomic Mapping of Copy Number and Structural Variation on Chromosome 1 (Chr1) Highlights Multiple Recurrent Disease Drivers

Defining Genomic Probability of Progression to Identify Low-Risk Smoldering Multiple Myeloma

Presence of Extrachromosomal DNA (ecDNA) Impacts Both Progression Free and Overall Survival and Is an Independent Poor Prognostic Marker in Multiple Myeloma

Clonal Hematopoiesis Is Frequent and Associated with Inferior Survival Irrespective of Transplantation Strategy in Patients with Newly Diagnosed Multiple Myeloma

In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present from the Diagnosis in Tiny Undetectable Subclones

Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2

Why is amyloidosis not multiple myeloma?

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma

Risk factors in multiple myeloma: is it time for a revision?

Undetectable MRD can change the deal

The Discriminatory Ability of the R-ISS Is Equivalent to the ISS in a Large Cohort of Newly Diagnosed Multiple Myeloma (NDMM) Patients

Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only